FIELD: biotechnology; genetic engineering.
SUBSTANCE: invention is a method of inserting a donor sequence into a predetermined insertion site on a chromosome in a host cell, comprising: introducing a guide RNA (gRNA) and an mRNA encoding a Cas enzyme into the host cell; and a composition comprising a lipid nanoparticle (LNP) containing a capsid-less closed-end DNA vector (ceDNA); wherein the ceDNA vector contains a nucleotide sequence between flanking inverted terminal repeats (ITR), wherein at least one nucleotide sequence is a gene-editing nucleic acid sequence containing a 5'-homologous arm, a repair template donor sequence and a 3'-homologous arm, and wherein the donor sequence is inserted into the chromosome at or near said insertion site by homologous recombination. The invention also relates to a method for editing chromosomal genes in a host cell, including introducing into the host cell a guide RNA (gRNA) and an mRNA encoding the Cas enzyme; and a composition comprising a lipid nanoparticle (LNP) containing a capsid-less closed-end DNA vector (ceDNA); wherein the ceDNA vector contains a nucleotide sequence between flanking inverted terminal repeats (ITRs), wherein at least one nucleotide sequence is a gene-editing nucleic acid sequence, wherein the gene-editing nucleic acid sequence contains a donor sequence, wherein said chromosome is restored using non-homologous end joining (NHEJ).
EFFECT: invention makes it possible to effectively insert a donor sequence into a certain part of the host cell chromosome.
62 cl, 19 dwg, 10 tbl, 18 ex
Title | Year | Author | Number |
---|---|---|---|
MODIFIED CLOSED CIRCULAR DNA (CCDNA) CONTAINING SYMMETRIC MODIFIED INVERTED END REPEATED SEQUENCES | 2019 |
|
RU2816963C2 |
MODIFIED CLOSED-ENDED DNA (scDNA) | 2018 |
|
RU2800026C2 |
CLOSED-ENDED DNA VECTORS OBTAINED BY CELL-FREE SYNTHESIS, AND METHOD OF PRODUCING CEDNA VECTORS | 2019 |
|
RU2820586C2 |
MODULATION OF REP PROTEIN ACTIVITY WHEN PRODUCING CLOSED-END DNA (ceDNA) | 2020 |
|
RU2812850C2 |
NON-VIRAL DNA VECTORS AND OPTIONS FOR THEIR USE FOR EXPRESSION OF THERAPEUTIC AGENT BASED ON PHENYLALANINE HYDROXYLASE (PAH) | 2020 |
|
RU2814137C2 |
NON-VIRAL DNA VECTORS AND THEIR USE FOR THE PRODUCTION OF ANTIBODIES AND FUSION PROTEINS | 2019 |
|
RU2800914C2 |
CLOSED-END LINEAR DUPLEX DNA FOR NON-VIRAL GENE TRANSFER | 2017 |
|
RU2752882C2 |
NON-VIRAL DNA VECTORS AND OPTIONS FOR THEIR USE FOR EXPRESSION OF THERAPEUTIC AGENT BASED ON FACTOR VIII (FVIII) | 2020 |
|
RU2812852C2 |
CONTROLLED EXPRESSION OF TRANSGENES USING CLOSED-END DNA VECTORS (ceDNA) | 2019 |
|
RU2816871C2 |
TRANSGENIC ANIMALS AND TRANSGENIC EMBRYOS PRODUCING ENGINEERED NUCLEASE | 2019 |
|
RU2817017C2 |
Authors
Dates
2024-01-16—Published
2018-12-06—Filed